Ovarian Cancer

Melissa Hardesty, MD, gynecologic oncologist, Alaska Women’s Cancer Center, discusses the safety and efficacy of the bevacizumab/PARP inhibitor combination in ovarian cancer.

Maurie Markman, MD, says that the acceleration in regulatory agency approvals for novel antineoplastic agents and the focus of biomarker discovery proves that this is the era of precision medicine.

David O'Malley, MD, discusses the emerging combination of mirvetuximab soravtansine plus bevacizumab and the evolving treatment landscape in ovarian cancer.

Taylor Turner, MD, fellow, University of Alabama at Birmingham School of Medicine, discusses important steps to implement a genomic profiling program for gynecologic malignancies.

David O'Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses folate-receptor alpha as a biomarker in ovarian cancer.

In combination with weekly paclitaxel, tumor treating fields, an antimitotic therapy that delivers continuous low-intensity electrical fields to the tumor region, has been found safe in platinum-resistant ovarian cancer.

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses response to PARP inhibitors in ovarian cancer.

Bradley J. Monk, MD, and other gynecologic oncology experts from across the United States discussed how new evidence has affected their approach to treating advanced ovarian cancer.

Kelly McCann, MD, PhD, a medical oncologist in the Breast Cancer Research Group at the University of California, Los Angeles, discusses resistance mutations in ovarian cancer.